Colorectal Cancer (CRC) — Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
Citation(s)
NGR006: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Colorectal Cancer (CRC), Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan Based Regimens